TIDMAPH

RNS Number : 8493R

Alliance Pharma PLC

09 November 2021

 
 For immediate release   9 November 2021 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Update on interim dividend timetable

In the Group's interim results for the six months ended 30 June 2021 announced on 21 September 2021, Alliance stated that its 2021 interim dividend payment of 0.563p per share (the "Interim Dividend") would be paid on 7 January 2022 to shareholders on the register on 24 December 2021.

Alliance would now like to update the market that it has brought forward the record date for the Interim Dividend to 17 December 2021, with the payment date remaining as 7 January 2022 as previously announced.

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Duncan Monteith 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                  + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DIVBLBDBSXGDGBC

(END) Dow Jones Newswires

November 09, 2021 11:36 ET (16:36 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Alliance Pharma Charts.